---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-198580"
form_type: "8-K"
ticker: "TSHA"
cik: "0001806310"
company_name: "Taysha Gene Therapies, Inc."
filed_at: "2023-07-31T23:59:59+00:00"
generated_at: "2026-06-12T22:13:14.824225+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Taysha Gene Therapies gets IDMC nod to continue REVEAL Phase 1/2 trial for TSHA-102 in Rett syndrome

## Summary
- IDMC recommended trial continuation after review of initial clinical data from first adult dosed with TSHA-102.
- Dosing of second patient expected in Q3 2023.
- Initial clinical update on first patient planned for Q2 2023 earnings call in mid-August.
- TSHA-102 is an AAV-based gene therapy for Rett syndrome due to MECP2 loss-of-function mutation.

## SEC filing metadata
- accession: 0001193125-23-198580
- form_type: 8-K
- ticker: TSHA
- cik: 0001806310
- company_name: Taysha Gene Therapies, Inc.
- filed_at: 2023-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806310/000119312523198580/0001193125-23-198580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806310/000119312523198580/d535611d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-198580
- JSON: https://secwatch.observer/filing/0001193125-23-198580.json
- Plain text: https://secwatch.observer/filing/0001193125-23-198580.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.